I came across this in the Retatrutide Phase II data appendix
The FDA told MEDVi that its site falsely suggested MEDVi was the compounder of the semaglutide and tirzepatide it sold, and that claims like Same active ingredient as Wegovy and Ozempic and Same active ingredient as Mounjaro and Zepbound falsely implied FDA approval or evaluation
[20] Thus, despite the wide variety of synapses, they all convey only these two types of messages
For exemestane, onset times were noted for alopecia, dry skin, erythema, hyperhidrosis, night sweats, onychoclasis, pruritus, rash, pruritic rash, and urticaria
This could lead to delayed onset of effects, potentially causing users to consume more thinking the initial dose was ineffective, resulting in eventual overconsumption when absorption finally occurs
doi: 10.1136/bmj.h56 78 HankeyGJ